前收市價 | 755.91 |
開市 | 743.00 |
買盤 | 740.00 x 1200 |
賣出價 | 740.00 x 900 |
今日波幅 | 730.34 - 745.00 |
52 週波幅 | 419.80 - 800.78 |
成交量 | |
平均成交量 | 3,117,708 |
市值 | 698.519B |
Beta 值 (5 年,每月) | 0.37 |
市盈率 (最近 12 個月) | 108.72 |
每股盈利 (最近 12 個月) | 6.76 |
業績公佈日 | 2024年4月30日 |
遠期股息及收益率 | 5.20 (0.71%) |
除息日 | 2024年2月14日 |
1 年預測目標價 | 855.36 |
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.
Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.
The anti-obesity medication stock is way up, and there could be more fuel in the tank.